Men with moderately advanced prostate cancer who get hormone-blocking drugs after radiation therapy do better when the drug treatment is continued for two or more years after an initial six-month regimen, a European study has found.
The results pretty much mirror those of a similar American trial reported in May, said Dr. Eric M. Horwitz, acting chairman of radiation oncology at Fox Chase Cancer Center in Philadelphia, who led the group that did the U.S. study.
"We have long believed that longer-term hormone therapy is the standard of care," Horwitz said. "These studies support that belief."
Read more at Forbes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment